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ABSTRACT: By screening a drug library comprising FDA
approved compounds, we discovered a potent interaction
between the antifungal agent haloprogin and the experimental
organometallic drug RAPTA-T, to synergistically induce
cancer cell killing. The combination of these two small
molecules, even at low doses, elicited an improved therapeutic
response on tumor growth over either agent alone or the
current treatment used in the clinic in the highly aggressive
syngeneic B16F10 melanoma tumor model, where classical
cytotoxic chemotherapeutic agents show little eﬃcacy. The combination with the repurposed chemodrug haloprogin provides the
basis for a new powerful treatment option for cutaneous melanoma. Importantly, because synergistic induction of tumor cell
death is achieved with low individual drug doses, and cellular targets for RAPTA-T are diﬀerent from those of classical
chemotherapeutic drugs, a therapeutic strategy based on this approach could avoid toxicities and potentially resistance
mechanisms, and could even inhibit metastatic progression.
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■ INTRODUCTION
Chemotherapy is a crucial part of the treatment plan for
thousands of patients with various early and late stage cancers.
The majority of drugs currently used in cancer chemotherapy
are cytotoxic drugs that share a similar mechanism of action;
speciﬁcally targeting dividing cells by interfering with DNA
synthesis, the DNA repair system or mitosis.1,2 Their
mechanism of action, therefore, does not distinguish between
normal and cancerous proliferating cells, a primary cause of side
eﬀects, such as bone marrow suppression and dose-limiting
toxicities.3 Another drawback that limits the use of current
chemotherapeutic drugs is the development of drug resistance.4
A possible way to advance cancer chemotherapy is to use
combinations of drugs in order to improve their therapeutic
eﬀects by inhibiting parallel pathways, potentially reducing the
incidence of drug-induced resistance. In addition, the
administration of drugs that act in an additive or synergistic
manner allows scaling down the drug dosage and thereby
decreasing toxicity; an approach that is already widely applied
in clinic.5−7 At the same time, there are many cancer types for
which treatment is limited or still nonexistent today, under-
lining the need for new chemotherapeutic drugs or other
treatment options.
Prompted by the success as well as the limitations in the use
of the chemotherapeutic agent cisplatin, several nonplatinum
metal-based compounds have been developed to produce less
toxic drug candidates that overcome cisplatin resistance.
Organometallic ruthenium compounds have emerged as
promising alternatives to currently used anticancer drugs by
displaying speciﬁc activities against diﬀerent cancers and
favorable toxicity and clearance properties.8−10 Many studies
indicate that the mechanism of action of such ruthenium
compounds is substantially diﬀerent to platinum-based drugs,
with other biomolecules, beyond DNA, being the primary
targets.11−13 Our laboratory has developed bifunctional
ruthenium agents of the type [Ru(η6-arene)Cl2(PTA)]
(where arene = benzene, toluene, p-cymene, etc.),14 with
RAPTA-T (where the arene = toluene) being one of them, that
exhibits low cytotoxicity in cell culture experiments, but is
proﬁcient at inhibiting both primary tumor growth and the
spreading and growth of solid metastatic tumors in mice.15
Experimental data demonstrate that ruthenium compounds are
able to sensitize cancer cells to drug-mediated apoptosis.16,17
Based on these ﬁndings, there is great hope in a combination
therapy where RAPTA-T and another drug could combine
their eﬀects by acting synergistically and lead to their use in
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much lower concentrations that would cause greatly reduced
harm to healthy, noncancerous cells.
Several studies have assessed the potential anticancer
properties of existing drugs and natural compounds that were
initially used for the treatment of non-neoplastic diseases.18−23
One recent study identiﬁed compounds from a pool of drugs
approved for other applications, that when combined with the
ruthenium compound NAMI-A led to improved cancer cell
killing.17 This so-called repurposing or repositioning approach
of existing drugs has the advantage that through preceding
research and development eﬀorts, the pharmacology, for-
mulation and toxicology of these agents in humans is
established, which would reduce the time and cost of approving
those compounds for clinical use in cancer therapy.24
With this objective, we designed an in vitro high-throughput
screen (HTS) with a library of clinically approved drugs to
identify novel anticancer agents that interact synergistically with
a low concentration of the experimental anticancer metallodrug
RAPTA-T to induce cancer cell killing. We show that the
antifungal agent, Haloprogin, together with RAPTA-T interact
synergistically to kill a variety of cancer cell types. Taking the
HTS approach as starting point to assess good drug
combinations with RAPTA-T, we further studied the
applicability and eﬀectiveness of the RAPTA-T/haloprogin
drug combination in vivo in an invasive mouse melanoma
model and explored whether the therapeutic eﬃcacy of
RAPTA-T was promoted by immunogenic cell death. Our
results demonstrate that RAPTA-T alone is highly eﬃcient in
inhibiting melanoma tumor growth at low concentrations. The
combination of RAPTA-T and haloprogin leads to an improved
therapeutic response over either agent alone and represent a
novel option for both classes of compounds in melanoma, and
potentially other cancer therapy.
■ EXPERIMENTAL SECTION
Cells, Culture Conditions, Compounds. B16F10 cells
were obtained from the American Type Culture Collection
(ATCC) and cultured in Glutamax RPMI (Life Technologies,
Switzerland) supplemented with 10% (v/v) FBS (PAN
Biotech, Germany) and 1 mM penicillin/streptomycin.
Human breast adenocarcinoma MDA-MB-231 (ATCC) cancer
cells were cultured in Glutamax DMEM medium (Life
Technologies, Switzerland) supplemented with 10% fetal
bovine serum. Tumor cells were grown in monolayers at 37
°C in a humidiﬁed CO2 incubator. Before reaching conﬂuence,
B16F10 cells were harvested with enzyme-free cell dissociation
buﬀer (EMD Millipore, Sigma-Aldrich, Switzerland), washed,
and suspended in PBS for injection. RAPTA-T was synthesized
as previously described.15 Haloprogin was purchased from
Sigma-Aldrich (Switzerland). The Prestwick Chemical Library
was purchased from Prestwick Chemical (Washington, DC)
and comprises 1280 small molecules, of which 90% are FDA
approved drugs, supplied at a concentration of 10 mM in
DMSO.
Prestwick Chemical Library High-Throughput Screen.
The Prestwick chemical library (PCL) (Prestwick Chemical,
France) used in this screen is composed of 1280 oﬀ-patent and
approved small molecule drugs of wide pharmacological
diversity. Plates were prepared in duplicates on which each
molecule was tested once. Negative control wells (16/384 per
assay plate) contained cells treated with 0.01% DMSO (ﬁnal
concentration) and positive control wells (16/384 per assay
plate) contained cells treated with CuSO4 (Sigma-Aldrich) at
10 μM. Dilution plates were prepared from original stock plates
(10 mM) in 100% DMSO by diluting the library with H2O to
10 μM. 384 well plates (Corning 3701, Switzerland) used for
the assay were prepared by the addition of 3 μL of 10 μM drug
to each well followed by the addition of 3 μL of RAPTA-T
solution (50 μM in respective cell culture medium) or 3 μL of
medium. Twenty-four microliters of cell suspension (10 000
cells) per well were added. After incubation for 24 h at 37 °C, 3
μL of PrestoBlue reagent (Thermo Fisher Scientiﬁc, Switzer-
land) was added to each well and the plates were incubated for
1 h in a cell incubator. The ﬂuorescence intensity was
quantiﬁed using a multiwell plate reader (ex560 nm/em590
nm, Tecan Inﬁnite F500). The results from the screens were
normalized to the controls for every plate and presented as
HTS scores, where a score of 0 corresponds to the average
ﬂuorescence intensity of the negative control wells (and
denotes no cytotoxic activity) and a score of 1 to that of the
positive control wells, indicating very active compounds.
Compounds were identiﬁed and statistically validated as PCL
hits when their HTS scores were higher than the average of the
negative controls +3 x SD. Compounds out of the PCL hits
were identiﬁed as ﬁnal hits when their average relative viability
levels were 1.5 times lower in the presence of RAPTA-T than
the respective average viability levels without RAPTA-T. An in-
house Laboratory Information Management System (LIMS)
was used for basic data processing, management, visualization,
and statistical hit validation.
The quality of the assay was estimated by calculating a Z′-
factor25 in which the maximal signal was deﬁned as the viability
of cells treated with RAPTA-T (50 μM) relative to the positive
control (CuSO4, 10 μM), and the minimum signal was deﬁned
as the background expressed by the positive control (100%
inhibition). The formula used to calculate the Z′-factor is 1−
3(SDmax − SDmin)/(Xmax − Xmin), where SD and X are the
standard deviation and average, respectively, of the maximal
signal (max) and the minimum signal (min). Signal-to-noise
ratio (S/N) was calculated using the following formula: S/N =
(Xmax − Xmin)/SDmin. The Z′-factor and S/N were determined
in 384-well plate formats in which half the plate was dosed with
RAPTA-T (50 μM) and half was dosed with the positive
control alone. The determined Z′ factor for this assay was 0.70
and the S/N ratio 298.
Cell Viability Assay. The PrestoBlue Cell Viability Assay
(Thermo Fisher Scientiﬁc, Switzerland) was used to determine
the eﬀects of monotreatment RAPTA-T, monotreatment
haloprogin, or combination treatment RAPTA-T and halopro-
gin on cancer cell proliferation. B16F10 cells were plated at a
density of 1.0 × 104 cells per well, in 96-well plates, and then
treated with RAPTA-T or haloprogin over a concentration
range from 12.5 to 800 μM for RAPTA-T and 5 to 50 μM for
haloprogin for 72 h. For the combination assays, cells were
treated with premixed concentrations of Haloprogin (25, 12.5,
6.25 μM) and RAPTA-T (500, 250, 125, and 62.5 μM). At the
end of treatments, 20 μL of the Presto Blue reagent were added
to each well. The plates were then incubated for 2 h at 37 °C in
the dark. All values were normalized with respect to the viability
of untreated cells. Four parameter dose−response curves were
created by using a variable slope model with GraphPad Prism
7.02.
Animal Experiments. Female C57BL/6 mice of age 5−6
weeks were purchased from Charles River, France. All animal
experiments were approved by the Institutional Animal Care
and Use Committee of the University of Lausanne. All
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procedures were carried out in accordance with the approved
guidelines.
Tumor Implantation, Treatment, Growth Measure-
ment. A total of 1 × 106 tumor cells in 100 μL of PBS were
injected s.c. into the shaved ﬂank of 7 week-old C57BL/6 mice.
At days 5, 7, 9, 12, 14, and 16 progressing tumors were injected
with 100 μL of PBS solution containing varying doses of
RAPTA-T (125, 250, 500, 1250 μg) or haloprogin (36 ng, 360
ng, 3.6 mg) or the combination of 250 μg RAPTA-T and 36 ng
haloprogin. cGAMP (10 μg per tumor) was injected as positive
control. The total number of immune cells upon RAPTA-T
treatment was not signiﬁcantly increased compared to PBS
control treatment. The tumor volume was measured with a
digital caliper every other day and calculated using the modiﬁed
ellipsoid formula V = (L × l2)/2, where L is the widest and l the
smallest diameter. Drug treatment eﬀect on tumor growth rate
was assessed by determining %T/Cday x calculated by [(mean
tumor volume of treated group on day X/mean tumor volume
of control vehicle group on day X) × 100]. Potentiation of
RAPTA-T eﬃcacy was assessed by comparing the tumor
growth inhibition eﬀect in the RAPTA-T monotherapy group
(CRT) to the tumor growth inhibition eﬀect by the RAPTA-T/
haloprogin combination group (TRT+H) on day X calculated by
[mean tumor volume of TRT+H/CRT × 100]. At the end of the
Figure 1. The Prestwick Chemical Library screen with human breast adenocarcinoma MDA-MB231 cells and human ovarian A2780 carcinoma cells.
(A) Schematic representation of the screening assay design. (B) Representative scatter plot of the PCL screen performed in duplicate (run 1 vs run
2) against A2780 cells. The results of two parallel runs are plotted against each other and show the reproducibility of the screen. Fluorescent intensity
of each compound was normalized to the corresponding controls on every plate and presented as HTS scores, where a score of 0 corresponds to the
average ﬂuorescence intensity of the negative control wells (and denotes “no cytotoxic activity”) and a score of 1 to that of the positive control wells
(10 μM CuSO4), indicating “very active compounds”. Out of 1280 compounds, 51 compounds were identiﬁed as PCL hits with an HTS score >0.2
against human ovarian A2780 carcinoma cells and 12 drugs were found to be eﬀective against MDA-MB-231 cells. (C) Representative screening data
of 1280 compounds tested against MDA-MB231 cells. The scatterplot shows the fold change in HTS score of PCL drug-treated wells relative to the
drug/RAPTA-T combination-treated wells for 1280 compounds. Five compounds showed a 1.5 fold increased inhibition of cell growth upon
RAPTA-T treatment and were identiﬁed as ﬁnal hits. (D) Scheme summarizing the results from two parallel screens, in the absence (PCL hits) and
presence of RAPTA-T, each performed in duplicate. The ﬁnal hits were identiﬁed based on a 1.5 fold increased HTS score for compounds in
combination with RAPTA-T compared to single drug treatment. The pool of ﬁnal hits consisted of 18 compounds (Table S1).
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experiment, tumors were harvested, embedded in OCT for
histology, or processed to generate a single cell suspension for
ﬂow cytometry analysis.
Generation and Analysis of Tumor Cell Suspensions
by Flow Cytometry Analysis. Tumors were harvested, rinsed
with PBS, and passed through a 70 μm cell strainer to obtain a
single cell suspension. Cells were stained with antibodies
against CD45 (30F11), CD3 (145.2C11), CD8a (53−6.7), and
CD4 (RM4−5) purchased from BD Pharmingen or eBio-
science. Data were acquired on a FACS Calibur (Becton
Dickinson), and analyzed with Flow-Jo V10 software.
Histology and Immunoﬂuorescence. For histopatho-
logical evaluation, 8 μm sections were cut with a cryostat,
thawed and mounted on Superfrost plus (Thermo Scientiﬁc)
slides, air-dried, and stored at −20 °C until further use. For
histology, tissue sections were stained with hematoxylin and
eosin. For immunohistochemistry, tissue sections were ﬁxed
with MeOH for 10 min at −20 °C, stained with anti-CD45
(MCD-4500, Life Technologies, clone 30-F11) primary
antibody (1:200), followed by donkey antirat biotinylated
secondary antibody (1:200), followed by alkaline phosphatase-
streptavidin (1:200) and Fast Red chromogen. Prior to
immunohistochemistry for cleaved caspase-3, tumor tissue
sections were ﬁxed in 4% PFA for 10 min at rt. After washing in
PBS, the sections were permeabilized with 0.25% Triton X-100
for 10 min, washed with PBS and blocked with 1% BSA. Then
the sections were incubated with the rabbit anticleaved caspase-
3 (Asp 175) antibody (1:200, #9661, Cell Signaling, Beverly,
MA) overnight at 4 °C. The donkey antirabbit Alexa568
(1:1000) secondary antibody was applied to locate the primary
antibody. Nuclear staining was performed with DAPI. Image
acquisition was performed using the Olympus Slide Scanner
VS120-L100.
Image Analysis and Quantiﬁcation. Images were
processed with Fiji. A threshold for each channel of interest
(COI, e.g. cleavedCasp3, DAPI) was set by autothreshold
(method: Default, Dark) and binary images were created from
which the number of stained objects and total number of nuclei
were determined by manual point counting. Eight random
ﬁelds per sample were selected and counted for all indices.
RNA Isolation and Gene Expression. Tumors were
homogenized in TRIzol (Invitrogen) and RNA was isolated
with chloroform and further isopropanol precipitation. The
concentration and purity of the RNA solution were determined
by using a NanoDrop spectrophotometer (ThermoFisher
Scientiﬁc). cDNA was obtained from 1 to 2 μg of total RNA
using SuperScript II reverse transcriptase (Invitrogen) accord-
ing to the manufacturer’s protocol. mRNA expression levels for
cytokines were analyzed using speciﬁc Taqman probes (Life
Technologies) and Taqman gene expression master mix (Life
Technologies). Ampliﬁcations were performed using the Step
One Real-Time PCR system (Applied Biosystem). The ΔCt
was used for statistical analysis, and the treated group values
were presented as fold of control mean value.
Statistical Analysis. All statistical analyses were performed
with GraphPad Prism 7.02 software. Test, group sizes, and P
values are given in the corresponding ﬁgure legends. P values
<0.05 were considered statistically signiﬁcant.
■ RESULTS
Prestwick Library Screen. The Prestwick Chemical
Library (PCL) used in this screen is composed of 1280 oﬀ-
patent, approved, small molecule drugs of wide pharmaco-
logical diversity. We screened these drugs against the human
breast adenocarcinoma MDA-MB231 and the human ovarian
A2780 carcinoma cancer cell lines as single drugs and in
combination with RAPTA-T using the PrestoBlue cell viability
assay to identify drugs that are more cytotoxic in the presence
of RAPTA-T than as single agent. Parallel screens were
performed in the presence and absence of RAPTA-T (Figure
1A). The concentration of RAPTA-T used in the screen was
determined by a prior titration with RAPTA-T on several
cancer cell lines. A concentration of 50 μM was chosen because
RAPTA-T has no cytotoxic eﬀect on cell growth at that
concentration (Figure S1). From the primary screen of the
entire PCL at a ﬁxed concentration of 10 μM, in the absence of
RAPTA-T and with a short incubation time of 24 h, 51 drugs
were found to be active against human ovarian A2780
carcinoma cells and 12 drugs were active against human breast
adenocarcinoma MDA-MB231 cells (named as PCL hits). The
reproducibility of two parallel screens is shown in Figure 1B.
Compounds were identiﬁed and statistically validated as hits
when their average HTS scores were 1.5 times higher in the
presence of RAPTA-T than the respective average HTS scores
without RAPTA-T (Figure 1C). Five compounds (partheno-
lide, mitoxantrone, chrysene-1,4-quinone, daunorubicin, and
haloprogin) from the screen against MDA-MB231 were
identiﬁed as ﬁnal hits when screened in the presence of
RAPTA-T, but which did not give a PCL hit when screened as
single agent only. The screen on A2780 cells gave 51 PCL hits,
out of which two compounds (isoetharine and primaquin) were
identiﬁed as ﬁnal hits with a higher HTS score in the presence
of RAPTA-T. Eleven additional compounds, which were not
PCL hits as single agent, were identiﬁed as ﬁnal hits in the
presence of RAPTA-T (Figure 1D). The pool of ﬁnal hits from
two separate screens performed on two cancer cell lines
comprised a total of 18 compounds. A list summarizing the hit
results with HTS score values and their pharmacological
classiﬁcation is given in the Supporting Information (Table S2).
Interestingly, ﬁnal hits detected in the MDA-MB231 cell
screen, were not found as hits in the A2780 cell screen and, the
ﬁnal hits of the A2780 cell screen did not lead to hits in MDA-
MB231 cells. Surprisingly, out of 18 hit compounds only two
compounds (mitoxantrone and daunorubicin) are chemo-
therapeutic agents. The other compounds may be classiﬁed as
anti-inﬂammatory, antiparasitic, or as adrenergic inhibitors, with
the majority of compounds assigned to the last class.
RAPTA-T Potentiates Cell Killing by Haloprogin. We
selected two compounds, parthenolide and haloprogin, out of
the HTS hit pool with interesting properties as repurposing
candidates, since they are drugs that are not already considered
chemotherapeutic drugs, but showed increased anticancer
activity in the presence of RAPTA-T. Parthenolide, a naturally
occurring sesquiterpene lactone of nucleophilic nature, allows
rapid interactions with biological sites. Its anticancer and pro-
apoptotic characteristics, through i.a. selective induction of
ROS in cancer cells have already been demonstrated.26−30
Haloprogin is a synthetic antifungal agent, administered
topically for dermatophytic infections.31,32 Its mechanism of
action is unknown, but it is believed to act through disruption
of the cytoplasmic membrane structure and function thereby
enhancing membrane permeability. It is therefore used only
topically.
The activity of the two drugs was conﬁrmed in dose−
response experiments against MDA-MB-231 and A2780 in
combination with RAPTA-T (Figure S3). Both compounds
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showed dose-dependent cytotoxic activity in both cell lines of
similar potency with IC50 values in the low micromolar range
(4−12 μM, 72 h drug exposure). Synergistic activities of both
compounds in combination with RAPTA-T were observed only
in MDA-MB231 cells, whereas in A2780 cells additive or even
antagonistic eﬀects predominated (Figure S4). This is in
accordance with the performed HTS screen, where both drugs
were identiﬁed as hits with the highly aggressive and invasive
cell line, MDA-MB231, but not with A2780 cells.
The property of haloprogin to enhance membrane
permeability caught our attention and triggered further
investigation of this molecule in combination with RAPTA-T.
We were intrigued by the possibility to test haloprogin on
melanoma since, for the prospect of its development as
anticancer drug, it could potentially be applied as its clinically
approved topical dosage form, as ointment or cream, directly
on the tumor site. For this reason, we chose the highly
proliferating B16F10 melanoma cell line with the prospect to
perform further testing of the Haloprogin/RAPTA-T-combi-
nation on a syngeneic orthotopic melanoma mouse model
known for its aggressive behavior.
The synergistic eﬀect of the RAPTA-T/haloprogin combi-
nation (for chemical structures see Figure 2A) shown before in
ovarian A2780 and breast MD-MB231 cancer cell lines, was
validated on murine B16F10 melanoma cells. Cells were
incubated with haloprogin (doses ranging from 6.25 to 25 μM)
combined with RAPTA-T (62.5−500 μM) and the cell viability
was measured after a drug exposure of 72 h using the
PrestoBlue cell viability assay. The strongest synergistic eﬀect
was obtained with 12.5 μM haloprogin (the approximate IC50-
72 h concentration) combined with low dose 62.5 or 125 μM
RAPTA-T (Figure 2B). The calculated combination indices,
Figure 2. RAPTA-T and haloprogin synergistically inhibit melanoma B16F10 cell viability. (A) Chemical structures of RAPTA-T (left) and
haloprogin (right). (B) Cells were treated with haloprogin (6.25−25 μM) alone and in combination with RAPTA-T (62.5−500 μM) for 72 h and
cytotoxicity determined by the Presto Blue assay after 72 h. The bar graphs depict drug-response relationships for the sensitization eﬀect of RAPTA-
T on the cytotoxicity of haloprogin, with the strongest eﬀect obtained with 12.5 μM haloprogin and low doses of RAPTA-T (shown in small bar
graph). (C) Combination indices as a function of RAPTA-T concentration. Values <0.9 indicate synergy, values >1.2 antagonism, values 0.9 < CI <
1.2 indicate an additive eﬀect.
Figure 3. RAPTA-T in monotherapy elicits antitumor activity against established subcutaneous murine B16F10 melanoma in C57BL/6
immunocompetent mice. (A) When the tumor reached a volume of 50−100 mm3, animals (N = 5 per group in each experiment) received ﬁve
intratumoral injections of either 1.25 mg, 250 μg, 125 μg or 62 μg of RAPTA-T at days 5, 7, 9, 12, and 14. The data are pooled from 3 independent
experiments. (B) Tumors on day 19 after (a) PBS and (b) 20 mgkg−1 RAPTA-T treatment. Phosphate-buﬀered saline (PBS) was used as a control
vehicle. Data represent mean tumor volumes ± SEM.
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which were 0.76 ± 0.09 (for 12.5 μM haloprogin combined
with 62.5 μM RAPTA-T) and 0.71 ± 0.02 for 12.5 μM
haloprogin combined with 125 μM RAPTA-T) conﬁrmed a
synergistic drug interaction in B16F10 melanoma cells (Figure
2C). The computed degree of synergism of the drug
combination can be described as “moderate synergism”
according to Chou.33 Notably, for certain mutual drug
concentrations the calculated combination index relates to
antagonism, which indicates that exact concentrations of the
individual drugs might be critical when used in combination for
cancer treatment.
RAPTA-T Inhibits B16F10 Melanoma Tumor Progres-
sion in Vivo. First, the eﬃcacy of RAPTA-T was tested in vivo
in the syngeneic B16F10 mouse melanoma model, a well-
established and widely used tumor model for which treatment
is notoriously diﬃcult.34,35 Starting 5 days after tumor cell
inoculation, when palpable tumors of 4−5 mm in diameter
developed, mice were treated on alternate days by intratumoral
injections of RAPTA-T at diﬀerent concentrations (100, 20, 10,
and 5 mgkg−1 body weight) for a total of 6 treatments (Figure
3A). A high dose of 100 mgkg−1 RAPTA-T turned out to be
toxic to the animals, however, reducing the concentration by a
factor of 5−20 led to equally high antitumor responses without
any signs of toxicity (e.g., overt signs of signiﬁcant weight loss,
dehydration, lack of grooming). The tumor volume was
reduced by >60% in all three groups treated with RAPTA-T
(5, 10, and 20 mgkg−1 body weight) compared to control
tumors treated with PBS vehicle (Table 1). During the course
of three independent experiments, RAPTA-T demonstrated
robust, consistent eﬃcacy in the B16F10 melanoma model.
Melanoma tissues of RAPTA-T treated tumors were analyzed
by histological examination to further investigate whether
tumor growth inhibition was induced by direct cytotoxicity of
RAPTA-T on tumor cells in vivo. We assessed possible
morphological changes in cell density, nuclei alteration and cell
death signals. The control group showed characteristics such as
large blood vessels, nuclear hyperchromasia, multinucleation,
and proliferating cell clusters, which are associated with intense
proliferative activity and conventional criteria for malignancy.
The RAPTA-T group showed pyknotic nuclei, decreased
nuclei/cytoplasmic ratio and nuclear degradation, which are
clear signals of cell death, mainly by apoptosis (Figure 4).
These characteristics were enhanced at the tumor periphery.
Necrotic areas in tumor tissue were not detected. To further
investigate the role of apoptosis, tumor sections were stained
for expression of cleaved caspase-3. RAPTA-T induced caspase-
3 expression in tumors was signiﬁcantly (P < 0.05) diﬀerent
compared to control tumors (Figure 4C). RAPTA-T treatment
showed 2.3-fold increased expression of cleaved caspase-3 in
tumors tissues compared to the control group (Figure 4D).
The observation that RAPTA-T induces apoptotic cell death in
vivo in the B16F10 melanoma model is particularly surprising
since in previous experiments RAPTA-T showed an apoptosis-
independent cell death mechanism.
Therapeutic Eﬃcacy of RAPTA-T Is Not Mediated by
an Anticancer Immune Response. We sought to evaluate
whether RAPTA-T recruits T-cells to cutaneous tumors and,
hence, is able to induce a localized inﬂammatory response that
could trigger anticancer immunity. We ﬁrst assessed the global
presence of immune cells by immunohistochemistry on tissue
sections of tumors treated with RAPTA-T (5 or 10 mgkg−1) or
PBS as a control vehicle using the pan-leukocyte marker CD45.
Tissue sections of tumor treated with cyclic dinucleotide GMP-
AMP (cGAMP) served as a positive control.36 We observed by
immunohistochemical analysis of the border region between
tumor mass and healthy tissue a higher density of CD45+
leukocytes in some tissue sections of RAPTA-T treated tumors
(Figure 5A). However, the total number of immune cells upon
RAPTA-T treatment was not signiﬁcantly increased compared
to PBS control treatment (Figure 5B). By quantitatively
assessing CD4+ and CD8+ T cell inﬁltration by ﬂow cytometry,
we found no signiﬁcant diﬀerences in the content of any T
lymphocyte type between RAPTA-T treated and PBS control
tumors (Figure 5C and D). Similar results were obtained for
Table 1. Eﬃcacy of RAPTA-T and Haloprogin Monotherapy and Combination Therapy in the B16F10 Murine Melanoma Flank
Tumor Modela
compound
(mg/kg/day)
mean tumor volume
(mm3 ± SEM) %T/Cveh (%TGI) ANOVA/Tukey
mean tumor volume
(mm3 ± SEM) %T/Cveh (%TGI) ANOVA/Tukey
study A day 16
RAPTA-T
100, i.t N/A
20, i.t 274 ± 73 22 (78) 0.02 N/A N/A N/A
10, i.t 416 ± 141 34 (66) ns
5, i.t 433 ± 123 35 (65) ns
haloproginb
0.144, i.t 931 ± 228 91 (9) ns N/A N/A N/A
0.014, i.t 804 ± 133 79 (21) ns
1.44 × 10−3, i.t 604 ± 224 59 (41) ns
study B day 16 day 19
RAPTA-T
20, i.t 274 ± 73 0.02 447 ± 139 35 (65) 0.008
haloprogin
1.44 × 10−3, i.t 574 ± 110 82 (18) 0.77 1327 ± 230 100 (0) 0.9
RAPTAT/haloprogin
20/1.44 × 10−3, i.t 157 ± 39 22 (78) 0.001 223 ± 59 17 (83) 0.001
a%T/C: drug-treated/appropriate vehicle-treated control tumor volume × 100; %TGI: percentage tumor growth inhibition (100%-T/C); N/A: not
applicable; ns: not signiﬁcant; i.t: intratumoral; the one-way ANOVA with Tukey’s posthoc test was applied for multi comparison; p values
correspond to comparison with the control group. bMean tumor volumes were assessed on day 14 when vehicle control group reached tumor end
point.
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the change of expression levels of inﬂammatory cytokines. IL1β,
IFNγ, TNFα, and IL12a were equally represented in treated
and PBS control tumors. An up-regulated expression of these
cytokines was not observed (Figure 5E). Based on these results,
we excluded an inﬂammatory response triggered by RAPTA-T.
Haloprogin Administered in Combination with
RAPTA-T Increases Inhibition of Melanoma Growth.
We tested the eﬃcacy of haloprogin monotherapy at diﬀerent
concentrations (1, 10, and 100 μM corresponding to 1.4, 14.4,
and 144 μgkg−1 body weight) on B16F10 tumor growth. Cells
were inoculated on both ﬂanks of mice. Established tumors on
both ﬂanks were treated by four intratumoral injections every
other day (on days 5, 7, 10, and 12). Since haloprogin is water-
insoluble, a stock solution was prepared in 100% EtOH and
serially diluted to the ﬁnal concentration in PBS, with EtOH
not exceeding 1% (v/v). The intratumoral injection of
haloprogin led to an inverse drug-response behavior on
tumor growth (Table 1). High doses (10 and 100 μM) of
haloprogin did not show any signiﬁcant tumor growth
inhibition compared to control injections with 1% EtOH,
whereas a low dose (1 μM) signiﬁcantly inhibited tumor
growth in three out of four mice (P = 0.0003, 2-way ANOVA).
Only one out of 8 tumors did not respond to the treatment
(Figure 6A).
To study the potential of the combination RAPTA-T/
haloprogin treatment, mice with one tumor on each ﬂank (N =
5 per group, 10 tumors) were treated over 2 weeks with a total
of six intratumoral injections of either monotherapy RAPTA-T
(250 μg), monotherapy haloprogin (1 μM) or the combination
thereof. Tumors on both ﬂanks were treated the same way.
Nine out of ten tumors treated with the RAPTA-T/haloprogin
combination showed signiﬁcantly lower tumor growth
compared to RAPTA-T treatment alone (P < 0.001, 2-way
ANOVA, Figure 6B). One tumor within this group did not
respond to the combination treatment. Haloprogin produced a
signiﬁcant potentiation by 50% of RAPTA-T eﬃcacy at day 19
compared to RAPTA-T monotherapy.
■ DISCUSSION
With the goal to investigate good drug combinations and
ideally, at the same time, identify potential novel anticancer
agents by making use of existing resources, we used an in vitro
high throughput screen (HTS) with a library of clinically
approved drugs37,23 that interact with the experimental
ruthenium drug RAPTA-T to induce cancer cell killing. We
could narrow the pool from 1280 approved drugs to 18 hit
compounds that led to enhanced activity when used in
combination in highly invasive human breast or ovarian cancer
Figure 4. RAPTA-T induces apoptosis in B16F10 melanoma of C57BL/6 mice. (A) The control group shows characteristics, such as (1) large blood
vessels, (2) proliferating cell cluster, (3) multinucleation, and (4) nuclear hyperchromasia. The RAPTA-T group (right panels) exhibit (5) pyknotic
nuclei, (6) a decreased nuclei/cytoplasmic ratio and (7) nuclear degradation, and (8) karyomegaly (enlarged cell nuclei). These characteristics are
enhanced at the tumor periphery (B); magniﬁcation: × 20. (C) Immunostaining of cleaved caspase 3 (red) as a measure of apoptotic cells death
indicate a higher apoptotic activity in tumors treated with RAPTA-T (right) compared to control (left). Nuclei have been stained with DAPI (blue).
Scale bar: 20 μm. (D) The apoptotic index as a measure of cleaved caspase 3 on tumor sections is signiﬁcantly higher in RAPTA-T treated tumors (P
= 0.036).
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cells. Among these drugs we found not only anticancer drugs,
but also other interesting drug classes including anti-
inﬂammatory and antiparasitic drugs and adrenergic inhibitors.
From this screen, we discovered a potent interaction between
haloprogin, an antifungal agent, and RAPTA-T. These two
small-molecule compounds, when combined, led to synergistic
activity in several cancer cell lines and showed an improved
therapeutic response on tumor growth over either agent alone
for cutaneous melanoma of mice.
Problems, such as chemo-resistance and systemic toxicity
with chemotherapeutic drugs are most often encountered with
melanoma. Alkylating agents in clinical use, such as dacarbazine
and temozolomide, comprise a unique family of cytotoxic drugs
that have demonstrated some eﬃcacy in melanoma patients,
however being only eﬀective in around 10−20% of cases having
received monotherapy. The cytotoxicity of these drugs is
attributed to the induced O6-methylguanine lesion.38 In this
respect, RAPTA-T with the ability to target other biomolecules
than DNA,16 could provide a possible alternative to conven-
tional chemotherapeutics in melanoma treatment. In addition,
the remarkably low general toxicity of RAPTA compounds and
haloprogin attributed to fast clearance from the organs and the
bloodstream through excretion by the kidneys make the two
compounds a promising combination for translation to clinical
evaluation.15,39,40
Remarkably, in our study, RAPTA-T even as monotherapy at
substantially lower concentrations elicited a very similar or even
greater antitumor response in the same mouse model compared
to the standard chemotherapeutic drugs dacarbazine and
temozolomide administered as single treatments.41−43 In
combination with haloprogin, the eﬃcacy of RAPTA-T was
signiﬁcantly potentiated by 50% compared to RAPTA-T
Figure 5. RAPTA-T does not recruit T lymphocytes to tumors. (A) Immunohistochemistry of CD45+ lymphocytes inside the B16F10 tumor mass,
marked by an asterisk, and in the peritumoral area, in + control (cGAMP), − control (PBS), and RAPTA-T treated groups (10 and 5 mgkg−1). Scale
bar: 100 μm. (B) Quantiﬁcation of the number of CD45+ cells in tumor tissue. (C) Flow cytometry dot plots of CD8+ and CD4+ T cells inﬁltrating
tumors. (D) Quantiﬁcation of the number of CD8+ and CD4+ T lymphocytes. Data are expressed as % cells of total tumor cells and represented as
mean ± SEM with N = 4−5 (ns, not signiﬁcant by unpaired t test). (E) Cytokine induction in response to intratumoral administration of RAPAT-T
(62.5 μg, 5 mgkg−1), PBS (− Ctrl) or cGAMP (+ Ctrl) at days 5, 7, 9, 12, and 14. Tumors were harvested at day 16 for RNA extraction. Analysis of
IL1β, TNFα, IFNγ, and IL12a gene expression was performed by quantitative PCR. ns, not signiﬁcant by unpaired t test.
Molecular Pharmaceutics Article
DOI: 10.1021/acs.molpharmaceut.7b00764
Mol. Pharmaceutics 2018, 15, 116−126
123
monotherapy. The eﬃcacy of the drug combination treatment
therefore is greatly enhanced compared to the standard agents
for melanoma treatment, dacarbazine, and temozolomide, used
in clinic.
Although anticancer drugs act mostly by direct induction of
apoptosis in cancer cells, many drugs may also promote
immunogenic cell death, which stimulates the antitumor
immune response and contributes to the therapeutic
eﬃcacy.44−47 Chemotherapeutics may also induce stress signals
leading to increased susceptibility of cancer cells to immune
attack or have the potential to reengineer the overall host
milieu and the local tumor microenvironment to disrupt
immune tolerance and suppression pathways.48 In melanoma,
mixed responses to chemotherapy are frequently observed.49
Various groups have shown in both preclinical models and in
cancer patients that several drugs can abrogate the suppressive
inﬂuence of regulatory T cells allowing eﬀective antitumor
immunity to emerge. Immunological eﬀector cells such as
CD3+ T-cells, CD45+ T-cells and macrophages reduce tumor
progression when inﬁltrated into cancer tissue.50
Among anticancer drugs, oxaliplatin and the ruthenium
compound NAMI-A are the only metal-based compounds for
which immunomodulatory eﬀects have been reported; NAMI-A
was shown to induce lymphocytes to inﬁltrate the tumor
mass,51 whereas oxaliplatin causes expression of immunogenic
signals on cancer cells prior to apoptosis, which in turn activates
the innate immune system and results in IFNγ production and
interaction with TLR4 of dendritic cells thereby creating a
tumor vaccine.52,53 Our results show that the tumor regression
induced by RAPTA-T, when administered intratumorally, is
unlikely to be mediated by tumor inﬁltrating T cells. Also
immune system activation through recruitment of macrophages
or dendritic cells may not play a role since the release of
cytokines, such as IL1β, TNFα, IFNγ, and IL12a, was not
signiﬁcantly increased in RAPTA-T treated tumors. Histo-
logical examination of tumor sections rather suggests a direct
cytotoxic eﬀect of RAPTA-T on B16F10 tumor cells.
In order to develop this combination treatment strategy as
cancer therapeutics further, a complete dose−eﬀect study in
vivo with varying concentrations of both drugs should be
performed to exclude possible antagonistic eﬀects seen in vitro.
In addition, it needs to be determined whether current
combination strategy with demonstrated eﬃcacy against local
tumors, would also eﬃciently prevent metastatic melanoma, the
main challenge for present and future systemic therapies. In this
respect, RAPTA-T with demonstrated antimetastatic potential
in reducing the number of metastases in lungs of mice with
mammary carcinoma might be worth to explore.15 For both
drugs, diﬀerent administration routes should be further
investigated since the current combination treatment strategy
with topical or intratumoral administration might only be
limited to treatment of local tumors.
In summary, our data suggest a strategy of inducing cancer
cell death with RAPTA-T as possible alternative to highly
cytotoxic chemotherapeutic agents in established melanoma
where classical chemotherapeutics have failed to be very much
eﬀective. Moreover, RAPTA-T proved to be a striking
candidate for its use in combination treatment with haloprogin,
in which the repurposed drug can be administered in very low
concentrations to potentiate RAPTA-T eﬃcacy and eﬃciently
inhibit melanoma growth. Whether such treatment might be
also eﬃcient against inhibiting metastatic spread and treating
metastases of melanoma has to be addressed in the future.
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(18) Goyeneche, A. A.; Caroń, R. W.; Telleria, C. M. Mifepristone
Inhibits Ovarian Cancer Cell Growth in Vitro and in Vivo. Clin. Cancer
Res. 2007, 13 (11), 3370−3379.
(19) Tieszen, C. R.; Goyeneche, A. A.; Brandhagen, B. N.; Ortbahn,
C. T.; Telleria, C. M. Antiprogestin Mifepristone Inhibits the Growth
of Cancer Cells of Reproductive and Non-Reproductive Origin
Regardless of Progesterone Receptor Expression. BMC Cancer 2011,
11, 207.
(20) Breitkreutz, I.; Anderson, K. C. Thalidomide in Multiple
Myeloma–Clinical Trials and Aspects of Drug Metabolism and
Toxicity. Expert Opin. Drug Metab. Toxicol. 2008, 4 (7), 973−985.
(21) Telleria, C. M. Drug Repurposing for Cancer Therapy. J. Cancer
Sci. Ther. 2012, 4 (7), ix−xi.
(22) Kenny, H. A.; Lal-Nag, M.; White, E. A.; Shen, M.; Chiang, C.-
Y.; Mitra, A. K.; Zhang, Y.; Curtis, M.; Schryver, E. M.; Bettis, S.;
Jadhav, A.; Boxer, M. B.; Li, Z.; Ferrer, M.; Lengyel, E. Quantitative
High Throughput Screening Using a Primary Human Three-
Dimensional Organotypic Culture Predicts in Vivo Efficacy. Nat.
Commun. 2015, 6, 6220.
(23) Varbanov, H. P.; Kuttler, F.; Banfi, D.; Turcatti, G.; Dyson, P. J.
Repositioning Approved Drugs for the Treatment of Problematic
Cancers Using a Screening Approach. PLoS One 2017, 12 (2),
e0171052.
(24) Nosengo, N. Can You Teach Old Drugs New Tricks? Nature
2016, 534 (7607), 314−316.
(25) Zhang, J.-H.; Chung, T. D. Y.; Oldenburg, K. R. A Simple
Statistical Parameter for Use in Evaluation and Validation of High
Throughput Screening Assays. J. Biomol. Screening 1999, 4 (2), 67−73.
(26) Juliana, C.; Fernandes-Alnemri, T.; Wu, J.; Datta, P.; Solorzano,
L.; Yu, J.-W.; Meng, R.; Quong, A. A.; Latz, E.; Scott, C. P.; Alnemri, E.
S. Anti-Inflammatory Compounds Parthenolide and Bay 11−7082 Are
Direct Inhibitors of the Inflammasome. J. Biol. Chem. 2010, 285 (13),
9792−9802.
(27) Nakshatri, H.; Rice, S. E.; Bhat-Nakshatri, P. Antitumor Agent
Parthenolide Reverses Resistance of Breast Cancer Cells to Tumor
Necrosis Factor-Related Apoptosis-Inducing Ligand through Sustained
Activation of c-Jun N-Terminal Kinase. Oncogene 2004, 23 (44),
7330−7344.
(28) Pajak, B.; Gajkowska, B.; Orzechowski, A. Molecular Basis of
Parthenolide-Dependent Proapoptotic Activity in Cancer Cells. Folia
Histochem. Cytobiol. 2008, 46 (2), 129−135.
(29) Zunino, S. J.; Ducore, J. M.; Storms, D. H. Parthenolide Induces
Significant Apoptosis and Production of Reactive Oxygen Species in
High-Risk Pre-B Leukemia Cells. Cancer Lett. 2007, 254 (1), 119−127.
(30) Zhang, S.; Ong, C.-N.; Shen, H.-M. Involvement of
Proapoptotic Bcl-2 Family Members in Parthenolide-Induced
Mitochondrial Dysfunction and Apoptosis. Cancer Lett. 2004, 211
(2), 175−188.
(31) Harrison, E. F.; Zwadyk, P.; Bequette, R. J.; Hamlow, E. E.;
Tavormina, P. A.; Zygmunt, W. A. Haloprogin: A Topical Antifungal
Agent. Appl. Microbiol. 1970, 19 (5), 746−750.
(32) Rezabek, G. H.; Friedman, A. D. Superficial Fungal Infections of
the Skin. Diagnosis and Current Treatment Recommendations. Drugs
1992, 43 (5), 674−682.
(33) Chou, T.-C. Theoretical Basis, Experimental Design, and
Computerized Simulation of Synergism and Antagonism in Drug
Combination Studies. Pharmacol. Rev. 2006, 58 (3), 621−681.
(34) Kuzu, O. F.; Nguyen, F. D.; Sharma, A.; Noory, M. Current
State of Animal (Mouse) Modeling in Melanoma Research. Cancer
Growth Metastasis 2015, 8s1, S21214.
(35) Brunda, M. J.; Luistro, L.; Warrier, R. R.; Wright, R. B.;
Hubbard, B. R.; Murphy, M.; Wolf, S. F.; Gately, M. K. Antitumor and
Antimetastatic Activity of Interleukin 12 against Murine Tumors. J.
Exp. Med. 1993, 178 (4), 1223−1230.
(36) Demaria, O.; De Gassart, A.; Coso, S.; Gestermann, N.; Di
Domizio, J.; Flatz, L.; Gaide, O.; Michielin, O.; Hwu, P.; Petrova, T.
V.; Martinon, F.; Modlin, R. L.; Speiser, D. E.; Gilliet, M. STING
Activation of Tumor Endothelial Cells Initiates Spontaneous and
Molecular Pharmaceutics Article
DOI: 10.1021/acs.molpharmaceut.7b00764
Mol. Pharmaceutics 2018, 15, 116−126
125
Therapeutic Antitumor Immunity. Proc. Natl. Acad. Sci. U. S. A. 2015,
112 (50), 15408−15413.
(37) Chong, C. R.; Xu, J.; Lu, J.; Bhat, S.; Sullivan, D. J.; Liu, J. O.
Inhibition of Angiogenesis by the Antifungal Drug Itraconazole. ACS
Chem. Biol. 2007, 2 (4), 263−270.
(38) Lage, H.; Christmann, M.; Kern, M. A.; Dietel, M.; Pick, M.;
Kaina, B.; Schadendorf, D. Expression of DNA Repair Proteins
HMSH2, HMSH6, HMLH1, O6-Methylguanine-DNA Methyltrans-
ferase and N-Methylpurine-DNA Glycosylase in Melanoma Cells with
Acquired Drug Resistance. Int. J. Cancer 1999, 80 (5), 744−750.
(39) Weiss, A.; Berndsen, R. H.; Dubois, M.; Müller, C.; Schibli, R.;
Griffioen, A. W.; Dyson, P. J.; Nowak-Sliwinska, P. In Vivo Anti-
Tumor Activity of the Organometallic Ruthenium(II)-Arene Complex
[Ru(H6-p-Cymene)Cl2(Pta)] (RAPTA-C) in Human Ovarian and
Colorectal Carcinomas. Chem. Sci. 2014, 5 (12), 4742−4748.
(40) Weikel, J. H.; Bartek, M. J. Toxicologic Properties and Metabolic
Fate of Haloprogin, an Antifungal Agent. Toxicol. Appl. Pharmacol.
1972, 22 (3), 375−386.
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